Work

TROP2‐targeted ADCs demonstrate survival benefit for patients with advanced triple‐negative breast cancer

Year: 2026

Type: article

Abstract: This news section offers Cancer readers timely information on events, public policy analysis, and topical issues. In this issue, TROP2‐targeted antibody–drug conjugates demonstrate a survival benefit for patients with advanced triple‐negative breast cancer. In addition, sacituzumab tirumotecan improved survival for patients with EGFR TKI–resistant, EGFR ‐mutant advanced non–small cell lung cancer, and an immunochemotherapy regimen demonstrates survival benefits for patients with platinum‐resistant ovarian cancer.

Source: Cancer

DOI: 10.1002/cncr.70249

Author: Leah Lawrence

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W7130612340

FWCI:

Cites: 2

Cited by:

Related to: